NanoSessions: Disruptive Technology is Being Used to Reduce Interruptions

 

A common refrain heard in the Pro AV space is the admiration for all of the newest technological advances. On this episode of NanoLumens’ NanoSessions, Joel Krieger, Chief Creative Officer for Second Story, sat down with host Sean Heath and they discussed how the newest disruptive technologies are being used in more subtle ways.

Generally speaking, digital displays have followed a path similar to that of the internet, according to Krieger.

“In the beginning, the internet was pretty interesting and it was like the Wild West. Eventually, it got commercialized and advertising began to really take over,” he said.

The digital display industry initially fell into the same pattern of prioritizing the advertising disruption, however, Krieger feels that is changing rapidly.

“We once again have a moment to kind of think about how we treat the ‘built environment’ and how we activate these canvases in a way that’s in service of the people and the business,” he explained.

The recent unveiling of a massive lobby installation, titled “Unify”, reinforces Krieger’s feeling that the next evolution of display technology application will be markedly different that the current digital modality.

“With Unify, we’re not trying to communicate a message; we’re trying to create a feeling for a space,” said Krieger. “There are other ways to calculate value or return on investment from a media piece and it’s not always ‘how many impressions of your advertising message can you get across?’.”

Redefining the purpose of the display is a way of acknowledging the impact of the message displayed on it, as well, according to Krieger.

“What’s the value of how your employees feel in your building? How do you put a value on that,” he asked.

For the latest news, videos, and podcasts in the Pro AV Industry, be sure to subscribe to our industry publication. A new episode of the Pro AV Show drops every Thursday.

Follow us on social media for the latest updates in B2B!

Twitter – @ProAVMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More